Blog

CRISPR Therapeutics Earnings Update: Maintains The Lead In Cas9 Clinical Trials – Seeking Alpha

CRISPR Therapeutics Earnings Update: Maintains The Lead In Cas9 Clinical Trials
Seeking Alpha
CRSP's update on their pipeline is encouraging – IND on track for 2017, first company in the CRISPR-Cas9 clinical space. Looking to address a large market with their lead product in ß-thallasemia and Sickle Cell Disease. Continuing to pay attention to
Head to Head Comparison: Crispr Theraptc (CRSP) and Editas Medicine (EDIT)Dispatch Tribunal


CRISPR THERAPTC (CRSP) Announces Earnings ResultsTrueBlueTribune
CRISPR Therapeutics AG (NasdaqGM:CRSP): A Look at Technicals & ValuationPearson Press

all 4 news articles »

2017-11-10 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.